Despite efforts by the FDA to ensure essential drug supplies, the number of drug shortages has stubbornly plateaued since 2018. Supply chain shortages during the COVID-19 pandemic have highlighted the sometimes-precarious situation of essential drug manufacturing, and recent disruptions in China and Russia have only further tightened the market, according to FiercePharma. Now, the FDA is working to prevent future supply chain shortages by requiring certain manufacturers to prepare risk management plans. In a draft guidance released May 19th, the agency announced that its new rules would affect manufacturers of drugs that are used to treat rare diseases, can be used during a public health crisis, and drugs which lack alternatives.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.